Cartesian Therapeutics
RNAC
83 hedge funds and large institutions have $43.9M invested in Cartesian Therapeutics in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 28 increasing their positions, 15 reducing their positions, and 11 closing their positions.
252% more capital inflows, than outflows
Capital inflows: $25.1M | Capital outflows: $7.14M
155% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 11
100% more call options, than puts
Call options by funds: $6K | Put options by funds: $3K
87% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 15
24% more funds holding
Funds holding: 67 → 83 (+16)
7.13% more ownership
Funds ownership: 19.85% → 26.98% (+7.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
+$15.8M |
| 2 |
Millennium Management
New York
|
+$855K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$599K |
| 4 |
Two Sigma Investments
New York
|
+$542K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$520K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.04M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$815K |
| 3 |
GSA Capital Partners
London,
United Kingdom
|
-$557K |
| 4 |
Erste Asset Management
Vienna,
Austria
|
-$356K |
| 5 |
Walleye Capital
New York
|
-$316K |
RNAC Hedge Fund Activity: Q1 2026 in Review
83 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2026, worth a combined $43.9M — up 18% from $37.2M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RNAC positions and 11 closed out — a net gain of 17 holders — while 28 added to existing stakes and 15 trimmed.
The largest buyer was Squarepoint, adding an estimated $15.8M. The largest seller was Fidelity Investments, cutting an estimated $4.04M.
- 83 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2026, up from 67 in Q4 2025.
- Funds reported $43.9M of Cartesian Therapeutics stock for Q1 2026, up 18% quarter-over-quarter.
- 28 funds opened new Cartesian Therapeutics positions in Q1 2026 and 11 closed out, a net change of +17 holders.
- The largest Cartesian Therapeutics buyer in Q1 2026 was Squarepoint, an estimated $15.8M added.
- The largest Cartesian Therapeutics seller in Q1 2026 was Fidelity Investments, an estimated $4.04M sold.
Based on aggregated 13F filings for Q1 2026.